Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATXINASDAQ:KZRNASDAQ:NCNANASDAQ:NEPTNASDAQ:SBBP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.20-16.5%$0.24$0.17▼$3.93$639K-0.09130,945 shs305 shsKZRKezar Life Sciences$4.58+3.2%$4.30$3.62▼$9.18$33.48M0.5852,691 shs52,977 shsNCNANuCana$0.06-33.2%$0.22$0.03▼$10.79$349K1.2536.75 million shs113.75 million shsNEPTNeptune Wellness Solutions$0.39$0.19▼$28.00$906K2.19462,687 shs2.25 million shsSBBPStrongbridge Biopharma$2.00$2.09$1.85▼$4.26$135.66M1.58866,464 shs684,684 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics0.00%-19.54%+10.33%-19.87%-93.13%KZRKezar Life Sciences0.00%-1.77%+6.47%-9.02%-26.00%NCNANuCana0.00%-14.10%+144.73%-90.16%-96.63%NEPTNeptune Wellness Solutions0.00%0.00%0.00%0.00%0.00%SBBPStrongbridge Biopharma0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATXIAvenue Therapeutics2.5292 of 5 stars0.04.00.04.62.20.01.9KZRKezar Life Sciences4.1947 of 5 stars3.23.00.04.62.71.70.6NCNANuCana3.098 of 5 stars3.32.00.00.03.32.51.3NEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AN/AN/AN/ASBBPStrongbridge BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXIAvenue Therapeutics 0.00N/AN/AN/AKZRKezar Life Sciences 2.33Hold$39.50762.45% UpsideNCNANuCana 2.50Moderate Buy$25.0043,454.01% UpsideNEPTNeptune Wellness Solutions 0.00N/AN/AN/ASBBPStrongbridge Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXIAvenue TherapeuticsN/AN/AN/AN/A$1.92 per shareN/AKZRKezar Life Sciences$7M4.78N/AN/A$16.02 per share0.29NCNANuCanaN/AN/AN/AN/A$1.34 per shareN/ANEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00SBBPStrongbridge Biopharma$30.73M4.41N/AN/A$0.98 per share2.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXIAvenue Therapeutics-$10.38M$18.350.01∞N/AN/A-471.57%-296.50%8/7/2025 (Estimated)KZRKezar Life Sciences-$83.74M-$10.82N/AN/AN/AN/A-61.15%-50.27%8/12/2025 (Estimated)NCNANuCana-$24.28M-$7.02N/AN/AN/AN/A-319.85%-88.55%8/13/2025 (Estimated)NEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%N/ASBBPStrongbridge Biopharma-$45.08M-$0.78N/AN/AN/A-115.67%-66.82%-36.21%N/ALatest SBBP, NEPT, NCNA, KZR, and ATXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/2/2025Q1 2025NCNANuCana-$0.0129-$0.63-$0.6171-$0.63N/AN/A5/13/2025Q1 2025KZRKezar Life Sciences-$2.56-$2.27+$0.29-$2.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXIAvenue TherapeuticsN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/ANCNANuCanaN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/ASBBPStrongbridge BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXIAvenue TherapeuticsN/A2.702.70KZRKezar Life Sciences0.047.097.09NCNANuCanaN/A1.251.25NEPTNeptune Wellness SolutionsN/A0.230.10SBBPStrongbridge Biopharma0.383.002.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXIAvenue Therapeutics17.34%KZRKezar Life Sciences67.90%NCNANuCana44.00%NEPTNeptune Wellness Solutions14.44%SBBPStrongbridge Biopharma52.03%Insider OwnershipCompanyInsider OwnershipATXIAvenue Therapeutics1.80%KZRKezar Life Sciences9.30%NCNANuCana31.20%NEPTNeptune Wellness Solutions5.10%SBBPStrongbridge Biopharma5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATXIAvenue Therapeutics43.18 million2.02 millionNot OptionableKZRKezar Life Sciences607.31 million6.63 millionNot OptionableNCNANuCana306.08 million4.18 millionNot OptionableNEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionableSBBPStrongbridge Biopharma7267.83 millionN/AOptionableSBBP, NEPT, NCNA, KZR, and ATXI HeadlinesRecent News About These CompaniesRising Investment in Patient Support Drives a Greater Biopharma Focus on MeasurementMarch 5, 2024 | fiercepharma.comFMatinas BioPharma Holdings Inc (MTNB)February 10, 2024 | investing.comLytix Biopharma As Share Price (LYTIX.OL)November 15, 2023 | lse.co.ukAmbrx Biopharma Inc AMAMNovember 4, 2023 | morningstar.comMBiopharma’s rapid transition to omnichannel marketingSeptember 11, 2023 | pharmaphorum.comPHILS Hillstream BioPharma, Inc.August 19, 2023 | seekingalpha.comABUS - Arbutus Biopharma CorporationJuly 1, 2023 | finance.yahoo.comThe Nominees for Best Biopharma CEO of 2015 Are...April 25, 2023 | thestreet.comDay One Biopharma Shares Rise 13% After Positive Topline Results for TovorafenibJanuary 11, 2023 | marketwatch.comBiopharma Soars to the Computational CloudsOctober 9, 2022 | genengnews.comGAccord BioPharma Partners with StoryMD to Deliver Advanced Prostate Cancer Educational Content to Clinicians and PatientsSeptember 22, 2022 | markets.businessinsider.comStrongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by ...September 23, 2021 | apnews.comAStrongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.September 23, 2021 | finance.yahoo.comPress Release: Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge BiopharmaSeptember 14, 2021 | sharecast.comSXeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge BiopharmaSeptember 14, 2021 | stockhouse.comStrongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris ...September 9, 2021 | apnews.comALeading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders ...August 31, 2021 | apnews.comASecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote "FOR" the Transaction With XerisAugust 31, 2021 | tmcnet.comSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With XerisAugust 31, 2021 | finance.yahoo.comStrongbridge Biopharma plc (NASDAQ: SBBP) Have Dropped -20.16% YTD, What Will Happen NextAugust 14, 2021 | marketingsentinel.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSBBP, NEPT, NCNA, KZR, and ATXI Company DescriptionsAvenue Therapeutics NASDAQ:ATXI$0.20 -0.04 (-16.51%) As of 09:30 AM EasternAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Kezar Life Sciences NASDAQ:KZR$4.58 +0.14 (+3.15%) As of 04:00 PM EasternKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.NuCana NASDAQ:NCNA$0.06 -0.03 (-33.18%) As of 04:00 PM EasternNuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.Neptune Wellness Solutions NASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. Strongbridge Biopharma NASDAQ:SBBPStrongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
